The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability

Neurobiology of Disease

Volumn 67, Issue , 2014, Pages 149-164

  Moliné Velázquez, Verónica ^a   Ortega, María Cristina ^a   Vila del Sol, Virginia ^a   Melero Jerez, Carolina ^a   de Castro, Fernando ^a   Clemente, Diego ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

Author keywords

Apoptosis; Dendritic cells; EAE; Immunomodulation; Lymphocyte; Neutrophil

Indexed keywords

RETINOID DERIVATIVE; TAMIBAROTENE; BENZOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DENSITY; CELL DIFFERENTIATION; CELL FATE; CELL POLARITY; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT RESPONSE; AGONISTS; ANIMAL; C57BL MOUSE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MYELOID PROGENITOR CELL; PATHOLOGY; SPINAL CORD; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BENZOATES; CELL DIFFERENTIATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELOID PROGENITOR CELLS; NEUTROPHILS; RECEPTORS, RETINOIC ACID; SPINAL CORD; T-LYMPHOCYTES; TETRAHYDRONAPHTHALENES;

EID: 84899558861     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.03.017     Document Type: Article

References (65)

1. Alabanza L.M., Esmon N.L., Esmon C.T., Bynoe M.S. Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells. J. Immunol. 2013, 191:3764-3777.
2. Almand B., Clark J.I., Nikitina E., van B.J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
3. Batoulis H., Addicks K., Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Ann. Anat. 2010, 192:179-193.
4. Berard J.L., Wolak K., Fournier S., David S. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 2010, 58:434-445.
5. Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 2009, 39:2670-2672.
6. Chen Z., Guidez F., Rousselot P., Agadir A., Chen S.J., Wang Z.Y., Degos L., Zelent A., Waxman S., Chomienne C. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1178-1182.
7. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
8. Constantinescu C.S., Farooqi N., O'Brien K., Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 2011, 164:1079-1106.
9. Cuenca A.G., Delano M.J., Kelly-Scumpia K.M., Moreno C., Scumpia P.O., Laface D.M., Heyworth P.G., Efron P.A., Moldawer L.L. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 2011, 17:281-292.
10. Dawson H.D., Collins G., Pyle R., Key M., Taub D.D. The retinoic acid receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production. BMC Immunol. 2008, 9:16.
11. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., O'Malley K.A., Wynn J.L., Antonenko S., Al-Quran S.Z., Swan R., Chung C.S., Atkinson M.A., Ramphal R., Gabrilovich D.I., Reeves W.H., Ayala A., Phillips J., Laface D., Heyworth P.G., Clare-Salzler M., Moldawer L.L. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204:1463-1474.
12. Díaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
13. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
14. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166:5398-5406.
15. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67:425.
16. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
17. Gallina G., Dolcetti L., Serafini P., De S.C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S., Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116:2777-2790.
18. Gervais A., Leveque J., Bouet-Toussaint F., Burtin F., Lesimple T., Sulpice L., Patard J.J., Genetet N., Catros-Quemener V. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res. 2005, 7:R326-R335.
19. Goni O., Alcaide P., Fresno M. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int. Immunol. 2002, 14:1125-1134.
20. Hengesbach L.M., Hoag K.A. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J. Nutr. 2004, 134:2653-2659.
21. Hestdal K., Ruscetti F.W., Ihle J.N., Jacobsen S.E., Dubois C.M., Kopp W.C., Longo D.L., Keller J.R. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 1991, 147:22-28.
22. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
23. Inglese M. Multiple sclerosis: new insights and trends. AJNR Am. J. Neuroradiol. 2006, 27:954-957.
24. Ioannou M., Alissafi T., Lazaridis I., Deraos G., Matsoukas J., Gravanis A., Mastorodemos V., Plaitakis A., Sharpe A., Boumpas D., Verginis P. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J. Immunol. 2012, 188:1136-1146.
25. Jimi S., Mashima K., Matsumoto T., Hara S., Suzumiya J., Tamura K. RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. Int. J. Oncol. 2007, 31:397-404.
26. Johnson B.S., Mueller L., Si J., Collins S.J. The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid receptors in different in vitro models of myeloid differentiation. Blood 2002, 99:746-753.
27. Jolivel V., Luessi F., Masri J., Kraus S.H., Hubo M., Poisa-Beiro L., Klebow S., Paterka M., Yogev N., Tumani H., Furlan R., Siffrin V., Jonuleit H., Zipp F., Waisman A. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013, 136:1048-1066.
28. Kagechika H., Kawachi E., Hashimoto Y., Himi T., Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 1988, 31:2182-2192.
29. King I.L., Dickendesher T.L., Segal B.M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113:3190-3197.
30. Klemann C., Raveney B.J., Klemann A.K., Ozawa T., von H.S., Shudo K., Oki S., Yamamura T. Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis. Am. J. Pathol. 2009, 174:2234-2245.
31. Kohanbash G., McKaveney K., Sakaki M., Ueda R., Mintz A.H., Amankulor N., Fujita M., Ohlfest J.R., Okada H. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res. 2013, 73:6413-6423.
32. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
33. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003, 63:4441-4449.
34. Lopez-Pedrera C., Barbarroja N., Buendia P., Torres A., Dorado G., Velasco F. Promyelocytic leukemia retinoid signaling targets regulate apoptosis, tissue factor and thrombomodulin expression. Haematologica 2004, 89:286-295.
35. Makarenkova V.P., Bansal V., Matta B.M. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 2006, 176:2085-2094.
36. Mildner A., Mack M., Schmidt H., Bruck W., Djukic M., Zabel M.D., Hille A., Priller J., Prinz M. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487-2500.
37. Miron V.E., Boyd A., Zhao J.W., Yuen T.J., Ruckh J.M., Shadrach J.L., van W.P., Wagers A.J., Williams A., Franklin R.J., Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013, 16:1211-1218.
38. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S., Gabrilovich D.I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.
39. Miwako I., Kagechika H. Tamibarotene. Drugs Today (Barc.) 2007, 43:563-568.
40. Moliné-Velázquez V., Cuervo H., Vila-Del S.V., Ortega M.C., Clemente D., de Castro F. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. Brain Pathol. 2011, 21:678-691.
41. Moreno B., Espejo C., Mestre L., Suardiaz M., Clemente D., de Castro F., Fernández-Fernández O., Montalban X., Villoslada P., Guaza C. Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis. Rev. Neurol. 2012, 54:114-124.
42. Movahedi K., Guilliams M., Van den B.J., Van den B.R., Gysemans C., Beschin A., De B.P., Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
43. Nagaraj S., Nelson A., Youn J.I., Cheng P., Quiceno D., Gabrilovich D.I. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012, 72:928-938.
44. Nagaraj S., Youn J.I., Gabrilovich D.I. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J. Immunol. 2013, 191:17-23.
45. Nefedova Y., Fishman M., Sherman S., Wang X., Beg A.A., Gabrilovich D.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67:11021-11028.
46. Ohnishi K. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int. J. Clin. Oncol. 2007, 12:313-317.
47. Ostrand-Rosenberg S., Sinha P., Beury D.W., Clements V.K. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 2012, 22:275-281.
48. Ring S., Maas M., Nettelbeck D.M., Enk A.H., Mahnke K. Targeting of autoantigens to DEC205+ dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice. J. Immunol. 2013, 191:2938-2947.
49. Rose S., Misharin A., Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry A 2012, 81:343-350.
50. Schmid M.C., Varner J.A. Myeloid cells in tumor inflammation. Vasc. Cell 2012, 4:14.
51. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
52. Slaney C.Y., Toker A., La F.A., Backstrom B.T., Harper J.L. Naive blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity. Immunol. Cell Biol. 2011, 89:7-13.
53. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 2007, 13:5243-5248.
54. Tobita T., Takeshita A., Kitamura K., Ohnishi K., Yanagi M., Hiraoka A., Karasuno T., Takeuchi M., Miyawaki S., Ueda R., Naoe T., Ohno R. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997, 90:967-973.
55. Toker A., Slaney C.Y., Backstrom B.T., Harper J.L. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2011, 74:235-243.
56. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
57. Ugel S., Zoso A., De S.C., Li Y., Marigo I., Zanovello P., Scarselli E., Cipriani B., Oelke M., Schneck J.P., Bronte V. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 2009, 69:9376-9384.
58. Walkley C.R., Yuan Y.D., Chandraratna R.A., McArthur G.A. Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis. Leukemia 2002, 16:1763-1772.
59. Wang Z., Sun G., Shen Z., Chen S., Chen Z. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin. Med. J. (Engl.) 1999, 112:963-967.
60. Wang J.X., Bair A.M., King S.L., Shnayder R., Huang Y.F., Shieh C.C., Soberman R.J., Fuhlbrigge R.C., Nigrovic P.A. Ly6G ligation blocks recruitment of neutrophils via a beta2-integrin-dependent mechanism. Blood 2012, 120:1489-1498.
61. Wu F., Cao W., Yang Y., Liu A. Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochem. Cell Biol. 2010, 133:313-322.
62. Youn J.I., Nagaraj S., Collazo M. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
63. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
64. Zhu B., Bando Y., Xiao S., Yang K., Anderson A.C., Kuchroo V.K., Khoury S.J. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:5228-5237.
65. Zhu B., Kennedy J.K., Wang Y., Sandoval-Garcia C., Cao L., Xiao S., Wu C., Elyaman W., Khoury S.J. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J. Immunol. 2011, 187:2418-2432.